+ enlarge

Long-term Relief of Symptoms

EFFEXOR XR is the first SNRI approved for panic disorder (PD).⁷ In a long-term 6-month study of adult patients with panic disorder, the cumulative probability of remaining relapse-free over 6 months was 76% with EFFEXOR XR vs. 55% with placebo.⁸*

• Randomized, placebo-controlled trial; open-label and double-blind phases^8†
• Patients treated to response with EFFEXOR XR (12 weeks) and then randomized to EFFEXOR XR or placebo⁸
• Patients randomized to EFFEXOR XR reported symptoms for an average of 4 years prior to study entry⁸

• *Relapse of panic disorder was defined as having 2 or more full-symptom (unexpected or situational) panic attacks per week for 2 consecutive weeks or as having been discontinued from the double-blind phase because of loss of effectiveness as determined by the investigators during the study. Trial population (intent-to-treat): EFFEXOR XR n=89, placebo n=80. P<0.001 EFFEXOR XR vs. placebo. Average daily dose during the double-blind phase ranged from 165 mg to 171 mg.
• †Patients who completed 12 weeks of open-label treatment with no clinically important ongoing adverse events and who met criteria for responder (1 or fewer full-symptom panic attacks per week during the last 2 weeks of open-label treatment and a CGI-I score of 1 or 2 based on improvement from open-label baseline) during the last 2 weeks of the open-label phase were randomly assigned to receive either EFFEXOR XR or placebo in a double-blind manner for up to an additional 6 months. CGI-I = Clinical Global Impression—Improvement scale.

+ enlarge

EFFEXOR XR: Proven Remission in Generalized Anxiety Disorder

At 6 months, more than twice as many patients treated with EFFEXOR XR had achieved remission vs. placebo (43% vs. 19%).⁹*

• Pooled analysis: 2 multicenter, double-blind, parallel-group, randomized, placebo-controlled trials in outpatients with DSM-IV^® criteria for GAD⁹
• Patients studied reported symptoms for an average of 9 years prior to study entry⁹

• *Remission was defined as HAM-A ≤7. Trial population (intent-to-treat): EFFEXOR XR n=514, placebo n=253. Last-observation-carried-forward (LOCF) analysis.
• Pooled data from 2 multicenter, randomized, double-blind, parallel-group, placebo-controlled trials in outpatients meeting DSM-IV^® criteria for GAD. Study A had a flexible-dose regimen, with all patients in the EFFEXOR XR treated group receiving 75 to 225 mg/day. After titration, the mean daily dose for EFFEXOR XR was between 143 and 176 mg. The EFFEXOR XR group was significantly better than placebo (P<0.001) based on primary efficacy measures. Study B had a fixed-dose regimen without titration: placebo and EFFEXOR XR 37.5, 75, and 150 mg/day. EFFEXOR XR 37.5 and 150 mg/day (P<0.001) and 75 mg/day (P<0.05) were significantly better than placebo based on primary efficacy measures.

EFFEXOR XR: Proven Remission of Social Anxiety Disorder Symptoms

Significantly more EFFEXOR XR patients (n=129) achieved remission of social anxiety disorder symptoms (LSAS ≤30) vs. placebo (n=132) (38% vs. 13%, respectively, P<0.001) in a randomized, double-blind, placebo-controlled study in patients experiencing symptoms for an average of approximately 18 years prior to study.¹⁰

• LSAS=Liebowitz Social Anxiety Scale.